World-First Gene Therapy Shows Remarkable Success in Three-Year-Old with Hunter Syndrome
核心洞察
Three-year-old Oliver Chu became the first person globally to receive groundbreaking gene therapy for Hunter syndrome (搜索), a rare genetic disorder that typically causes death before age 20.
Nine months post-treatment, Oliver is producing hundreds of times the normal amount of the missing enzyme and showing dramatic improvements in speech, mobility, and cognitive development.
The Manchester-based trial involves five boys worldwide and represents a potential breakthrough for treating rare genetic conditions affecting over 3.5 million people in the UK.
Three-year-old Oliver Chu has astounded medical researchers after becoming the first person worldwide to receive a revolutionary gene therapy for Hunter syndrome (搜索), a devastating rare genetic disorder that typically proves fatal before age 20. Nine months after treatment at Royal Manchester Children's Hospital, Oliver is thriving and producing the missing enzyme his body previously couldn't make.
Breakthrough Treatment for Devastating Disease
Hunter syndrome (搜索), also known as MPSII (搜索), affects one in 100,000 male births globally and causes progressive damage throughout the body and brain. The condition results from a faulty gene that prevents cells from producing iduronate-2-sulfatase (IDS), an enzyme essential for breaking down large sugar molecules. Without this enzyme, toxic substances accumulate in tissues and organs, leading to what researchers describe as a type of childhood dementia.
"I've been waiting 20 years to see a boy like Ollie doing as well as he is, and it's just so exciting," said Prof Simon Jones, who is co-leading the trial at Royal Manchester Children's Hospital.
Previously, the only available treatment was Elaprase, costing approximately £300,000 per patient annually. While this drug can slow physical symptoms, it cannot cross the blood-brain barrier to address cognitive decline.
Revolutionary Gene Therapy Process
The treatment involves a complex multi-step process beginning with stem cell collection. Oliver's blood was processed through specialized equipment to harvest stem cells, which were then transported to Great Ormond Street Hospital (搜索) in London for genetic modification.
Scientists inserted the missing IDS gene into a virus stripped of its disease-causing genetic material. Dr Karen Buckland from the Cell and Gene Therapy Service at GOSH explained: "We use the machinery from the virus to insert a working copy of the faulty gene into each of the stem cells. When those go back to Oliver, they should repopulate his bone marrow and start to produce new white blood cells and each of these will hopefully start to produce the missing protein [enzyme] in his body."
Crucially, researchers modified the inserted gene so the enzyme it produces can cross the blood-brain barrier more efficiently, addressing both physical and cognitive symptoms.
In February 2025, Oliver received approximately 125 million gene-modified stem cells through two infusions administered via chest catheter. The entire treatment was completed in a single day.
Dramatic Clinical Improvements
The results have exceeded expectations. Oliver's mother Jingru reported remarkable changes: "I want to pinch myself every time I tell people that Oliver is making his own enzymes. Every time we talk about it I want to cry because it's just so amazing."
Prof Jones documented the quantitative success: "Before the transplant Ollie didn't make any enzyme at all and now he's making hundreds of times the normal amount. But more importantly, we can see he's improving, he's learning, he's got new words and new skills and he's moving around much more easily."
Oliver's father Ricky described the transformation: "He's like a completely different child. He's running around everywhere, he won't stop talking. His speech, agility and cognitive development have all got dramatically better. It's not just a slow, gradual curve as he gets older, it has shot up exponentially since the transplant."
Most significantly, Oliver has been able to discontinue his weekly enzyme replacement therapy, as his body now produces the missing enzyme independently.
Expanding Trial and Future Implications
The trial includes five boys from the United States, Europe, and Australia, with all participants requiring monitoring for at least two years. Notably, no UK patients qualified for the trial as they were diagnosed too late to benefit from the treatment, which cannot reverse existing damage.
The same gene therapy approach is being applied to other mucopolysaccharidosis disorders, with similar treatments under trial in Manchester for MPS type 1 (搜索) (Hurler syndrome (搜索)) and MPS type 3 (搜索) (Sanfilippo syndrome (搜索)).
Funding Challenges Nearly Derailed Progress
The breakthrough almost never occurred due to funding difficulties. Researchers at the University of Manchester, led by Prof Brian Bigger, had spent over 15 years developing the gene therapy. After initially partnering with US biotech company Avrobio in 2020, the company returned the license three years later following poor results from another gene therapy study and funding shortages.
British charity LifeArc (搜索) rescued the trial by providing £2.5 million in funding. CEO Dr Sam Barrell noted: "A huge challenge for the more than 3.5 million people in the UK living with rare conditions, is getting access to effective treatments – currently 95% of conditions have none."
Looking Forward
If the trial proves successful, the hospital and university plan to partner with another biotech firm to pursue treatment licensing. The Chu family remains hopeful that Oliver's older brother Skyler, who also has Hunter syndrome (搜索) but was too old for the current trial, may eventually benefit from the same therapy.
Prof Jones maintains cautious optimism: "We need to be careful and not get carried away in the excitement of all this, but things are as good as they could be at this point in time."
The success represents a potential paradigm shift for treating rare genetic disorders, offering hope to families facing devastating diagnoses and demonstrating the transformative potential of gene therapy in pediatric medicine.